Literature DB >> 33656715

Emerging Technologies for the Treatment of COVID-19.

Hossein Aghamollaei1, Rahim Sarvestani2, Hamid Bakherad3, Hamed Zare4, Paul C Guest5, Reza Ranjbar6, Amirhossein Sahebkar7,8,9,10.   

Abstract

The new coronavirus, named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), turned into a pandemic affecting more than 200 countries. Due to the high rate of transmission and mortality, finding specific and effective treatment options for this infection is currently of urgent importance. Emerging technologies have created a promising platform for developing novel treatment options for various viral diseases such as the SARS-CoV-2 virus. Here, we have described potential novel therapeutic options based on the structure and pathophysiological mechanism of the SARS-CoV-2 virus, as well as the results of previous studies on similar viruses such as SARS and MERS. Many of these approaches can be used for controlling viral infection by reducing the viral damage or by increasing the potency of the host response. Owing to their high sensitivity, specificity, and reproducibility, siRNAs, aptamers, nanobodies, neutralizing antibodies, and different types of peptides can be used for interference with viral replication or for blocking internalization. Receptor agonists and interferon-inducing agents are also potential options to balance and enhance the innate immune response against SARS-CoV-2. Solid evidence on the efficacy and safety of such novel technologies is yet to be established although many well-designed clinical trials are underway to address these issues.

Entities:  

Keywords:  Biotechnology; COVID-19; Coronavirus; SARS-CoV-2; Treatment

Year:  2021        PMID: 33656715     DOI: 10.1007/978-3-030-59261-5_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  95 in total

Review 1.  RNAi and related mechanisms and their potential use for therapy.

Authors:  Reuven Agami
Journal:  Curr Opin Chem Biol       Date:  2002-12       Impact factor: 8.822

Review 2.  RNA interference: traveling in the cell and gaining functions?

Authors:  Heriberto Cerutti
Journal:  Trends Genet       Date:  2003-01       Impact factor: 11.639

3.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.

Authors:  Jianjun Gao; Zhenxue Tian; Xu Yang
Journal:  Biosci Trends       Date:  2020-02-19       Impact factor: 2.400

4.  Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings.

Authors:  C M Chu; V C C Cheng; I F N Hung; M M L Wong; K H Chan; K S Chan; R Y T Kao; L L M Poon; C L P Wong; Y Guan; J S M Peiris; K Y Yuen
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

5.  Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease.

Authors:  Maria L Agostini; Erica L Andres; Amy C Sims; Rachel L Graham; Timothy P Sheahan; Xiaotao Lu; Everett Clinton Smith; James Brett Case; Joy Y Feng; Robert Jordan; Adrian S Ray; Tomas Cihlar; Dustin Siegel; Richard L Mackman; Michael O Clarke; Ralph S Baric; Mark R Denison
Journal:  mBio       Date:  2018-03-06       Impact factor: 7.867

6.  Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase.

Authors:  Ariane J Brown; John J Won; Rachel L Graham; Kenneth H Dinnon; Amy C Sims; Joy Y Feng; Tomas Cihlar; Mark R Denison; Ralph S Baric; Timothy P Sheahan
Journal:  Antiviral Res       Date:  2019-06-21       Impact factor: 5.970

7.  Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection.

Authors:  Emmie de Wit; Friederike Feldmann; Jacqueline Cronin; Robert Jordan; Atsushi Okumura; Tina Thomas; Dana Scott; Tomas Cihlar; Heinz Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2020-02-13       Impact factor: 11.205

8.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

9.  Respiratory viral diseases: access to RNA interference therapy.

Authors:  Vira Bitko; Sailen Barik
Journal:  Drug Discov Today Ther Strateg       Date:  2007

10.  Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.

Authors:  Yaseen Arabi; Hanan Balkhy; Ali H Hajeer; Abderrezak Bouchama; Frederick G Hayden; Awad Al-Omari; Fahad M Al-Hameed; Yusri Taha; Nahoko Shindo; John Whitehead; Laura Merson; Sameera AlJohani; Khalid Al-Khairy; Gail Carson; Thomas C Luke; Lisa Hensley; Abdulaziz Al-Dawood; Saad Al-Qahtani; Kayvon Modjarrad; Musharaf Sadat; Gernot Rohde; Catherine Leport; Robert Fowler
Journal:  Springerplus       Date:  2015-11-19
View more
  1 in total

1.  A case-based systematic review on the SARS-COVID-2-associated cerebrovascular diseases and the possible virus routes of entry.

Authors:  Ali Lashkari; Reza Ranjbar
Journal:  J Neurovirol       Date:  2021-09-21       Impact factor: 2.643

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.